IFNG and neoplasm: Our data suggest that cellular immunotherapy using aATC with low levels of IL-2 and IFN-γ will not only target the tumor cells but may reverse the suppressive tumor environment to allow recruitment of CTLs and NK cells at the tumor sites and may induce an endogenous anti-tumor immune responses (Figure 5).